BrightFocus Editorial Staff
Sharyn Rossi, PhD Director, Neuroscience Programs, BrightFocus Foundation
Immune genes previously associated with higher Alzheimer’s risk may also be vulnerable to changes caused by individual lifestyle factors and behaviors, according to a new BrightFocus Foundation-funded study published in Neuron. The research team hopes their findings will eventually lead to new avenues for research into therapeutic targets.
Lead investigator David Gate, PhD, is a BrightFocus Alzheimer’s Disease Research grantee and assistant professor of neurology at Northwestern University. The research team investigated immune cells in the blood of individuals with Alzheimer’s disease.
They found that every type of immune cell showed modifications driven by a person’s behavior or environment, called “epigenetic” changes. These occur to the packaging, or chromatin, that surrounds DNA inside a cell. The cell’s DNA can become altered when the packaging is left open—a common sign of epigenetic changes.
Digging deeper, they uncovered that the immune cell genes most impacted by these changes are also known risk factors for Alzheimer’s disease. For example, researchers discovered a gene whose protein is thought to facilitate T-cell entry into the brain was particularly vulnerable to epigenetic changes.
The authors point to environmental factors or viral infection as possible instigators behind the modified genes.
“It is possible that these findings implicate the peripheral immune response in Alzheimer’s disease risk,” Dr. Gate said. “We haven’t yet untangled whether these changes are reflective of brain pathology or whether they precipitate the disease.”
Through Alzheimer’s Disease Research funding, Dr. Gate is using postmortem brain tissue samples and sophisticated molecular tools to determine if specific immune cells, called T-cells, appear in the same places as misfolded key proteins in Alzheimer’s disease. He earned the Alzheimer’s Disease Research Distinguished Investigator Award in 2023, awarded to the top-ranked grant proposal for that year.
Read the full story from Northwestern University.
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 51 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
Northwestern University Feinberg School of Medicine
Sinaptica Therapeutics unveils breakthrough Phase 2 results for an experimental non-invasive treatment for Alzheimer’s disease.
Get the latest in Alzheimer’s screening and treatments.
A BrightFocus-funded scientist is investigating a novel imaging tool that could be used to find treatable blood clots in the brain and slow the progression of Alzheimer’s disease.
Students and senior Alzheimer’s researchers gathered in Chicago for an immersive workshop hosted by BrightFocus Foundation.
"It's never too early in life or too late in life to reduce risk for dementia,” says Dr. Quincy Samus, a member of the Lancet Standing Commission on Dementia Prevention, Intervention, and Care. Learn more about two new ways to do so.
